Gyre Therapeutics (GYRE) CFO Chen received 50,000 Stock Option (Right to Buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Ruoyu Chen (Chief Financial Officer at Gyre Therapeutics Inc., GYRE) reported that they received 50,000 Stock Option (Right to Buy) on Jan 7, 2026.
- Reporting person
- Chen Ruoyu
- Role
- Chief Financial Officer
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 7, 2026 | Grant or award (A) | Stock Option (Right to Buy)On 50,000 Common Stock1 | +50,000 | - | - | 50,000 direct |
Holdings before and after
- Stock Option (Right to Buy): 0 to 50,000 direct
Footnotes from the filing
- 1. This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on January 7, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Chen report in this GYRE Form 4?
Ruoyu Chen (Chief Financial Officer at Gyre Therapeutics Inc., GYRE) reported that they received 50,000 Stock Option (Right to Buy) on Jan 7, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for GYRE
Earlier insider filings at GYRE
- Aug 26, 2025SEC Form 4 filed by Director Weng Dan
- Aug 8, 2025SEC Form 4 filed by Director Zhang Ping
- Jun 6, 2025SEC Form 4 filed by Director Epstein David M.
- Jun 6, 2025SEC Form 4 filed by Director Eastling Thomas Wilson
- Jun 6, 2025SEC Form 4 filed by Director Nussbaum Rodney L
Quantisnow market dataNASDAQ
GYRE
Gyre Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2006
Get push alerts for GYRE
Full GYRE profile on Quantisnow Follow GYRE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time